Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipelukast - MediciNova

Drug Profile

Tipelukast - MediciNova

Alternative Names: KCA-757; MN-001

Latest Information Update: 18 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer MediciNova
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Hepatoprotectants; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene receptor antagonists; Phospholipase C inhibitors; Thromboxane A2 receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • No development reported Interstitial cystitis
  • Discontinued Asthma

Most Recent Events

  • 15 Aug 2023 MediciNova receives patent allowance for Tipelukast in Europe for the treatment of scleroderma and/or systemic sclerosis
  • 14 Aug 2023 MediciNova receives notice of intention to Grant from the European Patent Office for Tipelukast for Nonalcoholic steatohepatitis in EU
  • 30 Apr 2023 MediciNova receives notice for patent allowance for Tipelukast for Nonalcoholic steatohepatitis in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top